In part 3 of this Exclusive Interview, Dr. Linda Siminerio talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California. Dr. Siminerio shares her choice for the most life-changing technology for patients.

In part 4 of this Exclusive Interview, Dr. Linda Siminerio explains the most important part of patient care in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 5, the conclusion, of this Exclusive Interview, Dr. Linda Siminerio talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about care for the prediabetes patient and the importance of doctors conveying the severity of the situation.

In part 6, the conclusion, of this Exclusive Interview, Dr. Linda Siminerio talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about her presentation goals for the provider audience.

If you put glycocalyx in Google search, you will find a definition that includes “a glycoprotein covering that surrounds the cell membranes of some bacteria, epithelia and other cells.” This does not make much sense when you’re trying to help prevent kidney disease, but this glycoprotein has a lot to do with …

Drs. Sood and Messer discuss the takeaways from their presentation with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas. They also share the advantages of working for a large organization versus private practice.

In this week's Homerun Slides, schema of the action of the Glycocalyx.

Insulin sensitivity based upon the OGTT: The previous discussion suggests that “quick and dirty” indices from fasting values may not be accurate, and it is often true that laboratory procedures are impractical. Recently, it has been suggested that indices calculated from the OGTT may be useful for population studies. For decades the OGTT has been used as a screening test and a diagnostic tool for diabetes and IGT. It might be ideal if one could classify the state of carbohydrate tolerance and simultaneously measure insulin sensitivity and beta-cell function.

It was not uncommon a few years ago to take a patient off metformin when they went on insulin. Metformin was considered a type 2 drug and when someone either had type 1 or they became insulin dependent there was no real value for metformin. I spent 13 years working …

Semaglutide trumps Trulicity in most recent trial.